New Blood Test to Help Diagnose Pancreatic Cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study tests a new blood test that uses epigenetics (chemical markers on DNA) to help diagnose pancreatic cancer. Researchers want to see if this test can accurately identify pancreatic cancer in people who have had it or are at high risk for developing it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older
- You must be a patient at University of Maryland Medical System (UMMS)
- You must be able to speak and understand English
- You must be willing to participate in study procedures and give informed consent
- You must either have a history of pancreatic cancer or be at high risk for developing pancreatic cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a new blood test that looks for chemical changes in your DNA (called epigenetics) to help diagnose breast cancer. If you are a patient at UMMS, your participation could help improve how breast cancer is detected.
This study is testing a new blood test to find pancreatic cancer early. It looks for tiny bits of cancer DNA floating in your blood, which could help catch the disease before symptoms start.
This study is testing a new blood test that looks for DNA changes to help find pancreatic cancer. It may lead to a way to find cancer earlier.
This trial studies how well a new blood-based test may help find pancreatic cancer earlier. You may join if you’re an adult who fits a specific risk group and can safely provide a blood sample.
This trial studies whether a blood-based test can help detect pancreatic cancer (or strong signs of it) earlier than usual. The goal is to see how well “liquid biopsy” results match real diagnoses and risk levels.
This study tests whether a blood test that looks at DNA changes (ctDNA methylation) can help predict how pancreatic cancer will behave and guide treatment decisions. It includes people with suspected pancreatic cancer who are planning surgery or a biopsy.
Hear when a new Pancreatic Cancer, Advanced or Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.